(NEW YORK)– International Endeavors Corporation
Post# of 127
(Total Views: 389)
Posted On: 11/08/2017 4:27:10 AM
(NEW YORK)– International Endeavors Corporation (OTCMKTS: IDVV) released outline on subsidiary partner KUBBY Cryogenics, Inc., and their use of their Cryogenic process in medical marijuana research.
In a recent release the Company stated, “Our Cryogenic process appears to trigger the production of Adult Stem Cells, based on independent research on the Endocannabinoid system and the entourage effect,” said Steve Kubby, CEO and President of Kubby Cryogenics. According to a recent peer reviewed study, the endocannabinoid system directs cell fate specification of Neural Stem Cells in the Central Nervous System, which can lead to new cell generation in the brain and the periphery systems.
https://www.ncbi.nlm.nih.gov/pubmed/24076098
Kubby Cryogenics manufacturing division produces a unique biomedicine from the raw cannabis plant. This new class of medicine is the company’s own proprietary method capturing the vitality of the raw plant in its extraction process.
This small batch, apothecary approach captures the live resins that have medical benefits for a number of ailments, including: cancer, inflammatory disease, epilepsy, brain injury, autism, Alzheimer’s.
According to the Company most people of all ages can potentially use Kubby Cryogenics because it’s naturally a non-psychoactive product.
IDVV Appoints New CEO
Steve Kubby, the new CEO of IDVV, played a key role in the passage of California Proposition 215, a ballot initiative passed in 1996 to legalize medical marijuana. He is a well-known cancer patient of 36 years, who benefits his recovery through the use of non-psychoactive Cryogenics, a raw cannabis extract. Steve Kubby was formally Chairman and CEO of Cannabis Sativa Inc. (OTCMKTS: CBDS), and has authored 2 books on drug policy reform. Mr. Kubby’s distinguished political career includes runs for Governor of California in 1998, and the 2008 Presidential primary race under the libertarian ticket.
Currently research being done focuses on the medical value in specific strains that may be used in the company’s proprietary Cryogenic process, a broad-spectrum therapy. Kubby Cryogenics is working with genetic partners to secure several medicinal strains to patent for this use.
This would place IDVV with similar pure medical marijuana plays such as GW Pharmaceuticals PLC ADR (NASDAQ:GWPH), Insys Therapeutics Inc. (NASDAQ:INSY), Nemus Bioscience Inc. (OTC:NMUS), Canopy Growth Corp. (OTC:TWMJF), OWC Pharmaceutical Research Corp (OTC:OWCP) India Globalization Capital, Inc. (NYSE: IGC), Freedom Leaf, Inc. (OTC:FRLF), and Medical Marijuana Inc. (OTC:MJNA) just to name a few.
About International Endeavors Corporation
International Endeavors Corporation is a company focused on biomedical uses of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the Company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases. www.internationalendeavorscorp.com
Disclaimer:
This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC”) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was compensated thirty thousand restricted shares for ongoing media advisory services on the companyt. WSNC, or its affiliates, may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.
Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
High Risk
Small and Micro cap, or ‘penny stocks’, involve a high degree of risk, and we highly encourage investors to consult with a financial advisor before making any and all investment decisions when investing in these type of securities.
In a recent release the Company stated, “Our Cryogenic process appears to trigger the production of Adult Stem Cells, based on independent research on the Endocannabinoid system and the entourage effect,” said Steve Kubby, CEO and President of Kubby Cryogenics. According to a recent peer reviewed study, the endocannabinoid system directs cell fate specification of Neural Stem Cells in the Central Nervous System, which can lead to new cell generation in the brain and the periphery systems.
https://www.ncbi.nlm.nih.gov/pubmed/24076098
Kubby Cryogenics manufacturing division produces a unique biomedicine from the raw cannabis plant. This new class of medicine is the company’s own proprietary method capturing the vitality of the raw plant in its extraction process.
This small batch, apothecary approach captures the live resins that have medical benefits for a number of ailments, including: cancer, inflammatory disease, epilepsy, brain injury, autism, Alzheimer’s.
According to the Company most people of all ages can potentially use Kubby Cryogenics because it’s naturally a non-psychoactive product.
IDVV Appoints New CEO
Steve Kubby, the new CEO of IDVV, played a key role in the passage of California Proposition 215, a ballot initiative passed in 1996 to legalize medical marijuana. He is a well-known cancer patient of 36 years, who benefits his recovery through the use of non-psychoactive Cryogenics, a raw cannabis extract. Steve Kubby was formally Chairman and CEO of Cannabis Sativa Inc. (OTCMKTS: CBDS), and has authored 2 books on drug policy reform. Mr. Kubby’s distinguished political career includes runs for Governor of California in 1998, and the 2008 Presidential primary race under the libertarian ticket.
Currently research being done focuses on the medical value in specific strains that may be used in the company’s proprietary Cryogenic process, a broad-spectrum therapy. Kubby Cryogenics is working with genetic partners to secure several medicinal strains to patent for this use.
This would place IDVV with similar pure medical marijuana plays such as GW Pharmaceuticals PLC ADR (NASDAQ:GWPH), Insys Therapeutics Inc. (NASDAQ:INSY), Nemus Bioscience Inc. (OTC:NMUS), Canopy Growth Corp. (OTC:TWMJF), OWC Pharmaceutical Research Corp (OTC:OWCP) India Globalization Capital, Inc. (NYSE: IGC), Freedom Leaf, Inc. (OTC:FRLF), and Medical Marijuana Inc. (OTC:MJNA) just to name a few.
About International Endeavors Corporation
International Endeavors Corporation is a company focused on biomedical uses of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the Company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases. www.internationalendeavorscorp.com
Disclaimer:
This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC”) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was compensated thirty thousand restricted shares for ongoing media advisory services on the companyt. WSNC, or its affiliates, may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.
Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
High Risk
Small and Micro cap, or ‘penny stocks’, involve a high degree of risk, and we highly encourage investors to consult with a financial advisor before making any and all investment decisions when investing in these type of securities.
(0)
(0)Scroll down for more posts ▼